Sucampo Pharmaceuticals, Inc. has amended its existing collaboration and license agreement with Takeda Pharmaceutical Co. covering the U.S. and Canada for AMITIZA (lubiprostone). The current term has been extended, along with minimum commercial investment and various governance changes allowing Takeda additional flexibility in commercializing AMITIZA.   During the extended term beginning January 1, 2021, Takeda will split with Sucampo the profits of branded AMITIZA for any dosage strength and fo...